Concepedia

LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

Mustafa Özgüroğlu, A. Sezer, Igor Bondarenko, M. Gogishvili, Marina Nechaeva, M. Schenker, Gwo Fuang Ho, Y. Kulyaba, Mikhail Dvorkin, K. Zyuhal,

Annals of Oncology · 2022 · 10 citations · 0 references

Open access

Concepts

MedicineOncologyPharmacologyCancer PharmacologyChemotherapyTumor ProgressionCancer ImmunotherapyCancer Survival AnalysisLung CancerLung Cancer PharmacotherapyMalignant NeoplasmsNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer Treatment